-
Innovation Ranking
NewInnovation Ranking – Verastem Inc
Verastem Inc (Verastem) is a biopharmaceutical company. It carries out the discovery, development, and commercialization of novel small molecule drugs to treat cancer. The company’s most advanced product candidates include VS-6766, defactinib (VS-6063). Verastem products VS-6766 and defactinib (VS-6063), are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including, low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, uveal melanoma, and endometrial cancer. The pipeline products focused...
-
Product Insights
NewNet Present Value Model: Verastem Inc’s Avutometinib Potassium
Empower your strategies with our Net Present Value Model: Verastem Inc's Avutometinib Potassium report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Avutometinib Potassium in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Avutometinib Potassium in Cervical Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Avutometinib Potassium in Cervical Cancer Drug Details: Avutometinib potassium (RG-7304,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BCMA NKE in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BCMA NKE in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BCMA NKE in Relapsed Multiple Myeloma Drug Details: BCMA NKE...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Defactinib Hydrochloride in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Defactinib Hydrochloride in Fallopian Tube Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Defactinib Hydrochloride in Fallopian Tube Cancer Drug Details: Defactinib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Defactinib Hydrochloride in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Defactinib Hydrochloride in Peritoneal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Defactinib Hydrochloride in Peritoneal Cancer Drug Details: Defactinib hydrochloride (VS-6063)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Defactinib Hydrochloride in Metastatic Uveal Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Defactinib Hydrochloride in Metastatic Uveal Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Defactinib Hydrochloride in Metastatic Uveal Melanoma Drug Details: Defactinib...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Defactinib Hydrochloride in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Defactinib Hydrochloride in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Defactinib Hydrochloride in Non-Small Cell Lung Cancer Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Defactinib Hydrochloride in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Defactinib Hydrochloride in Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Defactinib Hydrochloride in Colorectal Cancer Drug Details: Defactinib hydrochloride (VS-6063) is...